Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of TAS-102 + fruquintinib + sintilimab in MSS metastatic colorectal cancer after standard therapy failure
ChiCTR2400089944Phase 2Recruiting
- Sponsor
- Sun Yat-sen University Cancer Center
- Start
- Sep 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of trifluridine + tipiracil, fruquintinib and sintilimab, sponsored by Sun Yat-sen University Cancer Center. Started Sep 2024; status: recruiting.
02
Drugs
trifluridine + tipiracilfruquintinibsintilimab
Beyond the preview
Go deeper on ChiCTR2400089944.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400089944.